Risk of acute renal failure associated with combined use of SGLT2 inhibitors and potentially nephrotoxic drugs: an epidemiological surveillance study based on the FDA adverse event reporting system (FAERS)

Background Limited knowledge exists regarding nephrotoxic risksassociated with the combination of sodium-glucose co-transporter-2 inhibitors(SGLT2i) and potentially nephrotoxic drugs. This study evaluates acute renalfailure (ARF) events linked to such combinations using data from the FDAAdverse Event Reporting System (FAERS).